Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia

Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia

Background Standard of care (SoC) for transfusion-dependent β-thalassemia (TDT) requires lifelong, regular blood transfusions as well as chelation to reduce iron accumulation. Objective This study investigates the cost-effectiveness of betibeglogene autotemcel (‘beti-cel’; LentiGlobin for β-thalasse...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Anuraag R. Kansal, Odette S. Reifsnider, Sarah B. Brand, Neil Hawkins, Anna Coughlan, Shujun Li, Lael Cragin, Clark Paramore, Andrew C. Dietz, J. Jaime Caro
Formato: article
Lenguaje:EN
Publicado: Taylor & Francis Group 2021
Materias:
beta-thalassemia
economic evaluation
gene therapy
Public aspects of medicine
RA1-1270
Business
HF5001-6182
Acceso en línea:https://doaj.org/article/d6cb861054544eae9f3fd0425864a1ec
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/d6cb861054544eae9f3fd0425864a1ec

Ejemplares similares